Pacific Biosciences Of California (PACB) Other Accumulated Expenses (2011 - 2026)

Pacific Biosciences Of California's Other Accumulated Expenses history runs 16 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 77.83% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 77.83% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 37.0% from the prior year.
• Other Accumulated Expenses declined to $1.2 million in Q1 2026 per PACB's latest filing, from $2.0 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $8.3 million in Q4 2023 and bottomed at $783000.0 in Q3 2024.
• The 5-year median for Other Accumulated Expenses is $4.6 million (2022), against an average of $4.3 million.
• Across the five-year window, Other Accumulated Expenses soared 351.78% in 2022 and plunged 84.85% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $7.2 million in 2022, then gained by 15.11% to $8.3 million in 2023, then plunged by 61.28% to $3.2 million in 2024, then plunged by 37.0% to $2.0 million in 2025, then slumped by 39.19% to $1.2 million in 2026.
• Per Business Quant, the three latest PACB Other Accumulated Expenses figures stand at $1.2 million (Q1 2026), $2.0 million (Q4 2025), and $1.0 million (Q3 2025).